Table 1 Summary of the demographic data
GROUP 1 | GROUP 2 | GROUP 3 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mean ± s.d /n-% | Med | Mean ± s.d /n-% | Med | Mean ± s.d /n-% | Med | ||||||||||
Age | 61.9 | ± | 10.2 | 65.0 | 58.7 | ± | 8.7 | 58.0 | 57.0 | ± | 6.5 | 57.0 | 0.009 | K | |
Gender | Female | 19 | 54.3% | 13 | 48.1% | 13 | 41.9% | 0.605 | X2 | ||||||
Male | 16 | 45.7% | 14 | 51.9% | 18 | 58.1% | |||||||||
Number of Anti-VEGF | 5.4 | ± | 1.8 | 5.0 | 7.1 | ± | 2.4 | 7.0 | 7.0 | ± | 2.7 | 7.0 | 0.004 | K | |
HbA1c | 8.0 | ± | 2.1 | 8.2 | 8.2 | ± | 2.2 | 7.7 | 8.3 | ± | 2.0 | 8.2 | 0.872 | K | |
Anti-VEGF Name | Aflibercept | 19 | 54.3% | 10 | 37.0% | 15 | 48.4% | 0.398 | X2 | ||||||
Ranibizumab | 16 | 45.7% | 17 | 63.0% | 16 | 51.6% | |||||||||
Follow-Up Month | 25.1 | ± | 1.7 | 25.0 | 24.8 | ± | 1.5 | 25.0 | 25.2 | ± | 1.4 | 25.0 | 0.679 | K | |